Home › All Companies › BYSI › Quarterly Report

BeyondSpring Inc. (BYSI) — Quarterly Report

AI-Powered SEC Filing Analysis

← All BYSI filings
Latest Quarterly Report Filed: 2026-05-13

Key Insights

  • The filing content provided is primarily XBRL metadata and structural tags without substantive financial data, revenue figures, or operational metrics necessary for meaningful analysis of BeyondSpring's Q1 2026 performance.
  • References to multiple subsidiary entities (SEED Therapeutics Inc, Wanchun entities, BeyondSpring HK) indicate complex international operations across US and China, suggesting potential exposure to regulatory and geopolitical risks.
  • Mentions of research collaboration agreements with Eli Lilly and various financing rounds (Series A3) suggest the company is progressing development partnerships, though actual financial results and clinical milestones are not visible in the provided excerpt.
Sentiment: Neutral Significance: 2/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-05-13. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for BeyondSpring Inc.

Current Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.